One & One Green Technologies stock soars 100% after IPO debut
CHELMSFORD, Mass. - Asahi Kasei (Market Cap: $10.8B) announced Thursday that its ZOLL Zenix monitor/defibrillator has received premarket approval from the U.S. Food and Drug Administration. The device, designed for emergency medical services and hospital settings, features a touchscreen interface and automated workflow capabilities. According to InvestingPro analysis, Asahi Kasei appears undervalued, with strong momentum reflected in its 33% price return over the past six months.
The Zenix monitor/defibrillator includes ZOLL’s Real BVM Help and Real CPR Help technologies, allowing users to make real-time adjustments during critical care situations. The company states the device was developed based on years of user feedback.
"This device has been designed with an understanding of customer needs," said Ken Shinomiya, Leader of the Healthcare Sector at Asahi Kasei, in the press release.
ZOLL has been a significant growth driver for Asahi Kasei’s Healthcare sector since its acquisition in 2012, reportedly increasing net sales fivefold and operating income sevenfold. The company identifies the Zenix monitor/defibrillator as part of its strategy to maintain market competitiveness through new product introductions.
The device is now available to customers in the United States and Canada, according to the company statement.
Asahi Kasei, a global provider of healthcare technology and pharmaceutical solutions, includes ZOLL in its portfolio of critical care products that support the company’s long-term corporate development goals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.